Evidence map›Paper›PMID 38331802›Full record

ArticleBMC health services research2024

A survey of barriers and facilitators to the adoption of buprenorphine prescribing after implementation of a New Jersey-wide incentivized DATA-2000 waiver training program.

Amesika N Nyaku, Erin A Zerbo, Clement Chen, Nicole Milano, Barbara Johnston, Randall Chadwick, Stephanie Marcello, Kaitlan Baston, Rachel Haroz, Stephen Crystal

Open access · goldAbstract read
In one paragraph

Article in BMC health services research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Amesika N NyakuDepartment of Medicine, Division of Infectious Diseases, Rutgers New Jersey Medical School, 185 South Orange Ave, MSB I689, Newark, NJ, 07103, USA. Amesika.nyaku@rutgers.edu.
Erin A ZerboPrivate Practice, Montclair, NJ, 07042, USA.
Clement ChenDepartment of Psychiatry, Rutgers New Jersey Medical School, 183 South Orange Ave, BHSB F-Level, Newark, NJ, 07103, USA.
Nicole MilanoMental Health Association in New Jersey, 673 Morris Avenue, Suite 100, Springfield, NJ, 07781, USA.
Barbara JohnstonMental Health Association in New Jersey, 673 Morris Avenue, Suite 100, Springfield, NJ, 07781, USA.
Randall ChadwickRutgers University Behavioral Health Care, 151 Centennial Avenue, Suite 1140, Piscataway, NJ, 08854, USA.
Stephanie MarcelloRutgers University Behavioral Health Care, 151 Centennial Avenue, Suite 1140, Piscataway, NJ, 08854, USA.
Kaitlan BastonDepartment of Internal Medicine, Cooper Medical School of Rowan University, Three Cooper Plaza, Camden, NJ, 08103, USA.
Rachel HarozDepartment of Emergency Medicine, Cooper Medical School of Rowan University, One Cooper Plaza, Camden, NJ, 08103, USA.
Stephen CrystalCenter for Health Services Research, Institute for Health, Health Care Policy and Aging Research, Rutgers, the State University of New Jersey, 112 Paterson St, 3rd Floor, New Brunswick, NJ, 08901, USA.
Rutgers, The State University of New Jersey · USCooper Medical School of Rowan University · US

Funding

Opioid Overdoses among Medicaid Beneficiaries: Predictors, Outcomes, and State Policy EffectsR01DA047347 · NIDA · RUTGERS, THE STATE UNIV OF N.J. · PI CRYSTAL, STEPHEN · 2019 to 2022
$3.1M
Implementing Integrated Services for People With HIV and Opioid Use DisorderK23DA053989 · NIDA · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI NYAKU, AMESIKA · 2021 to 2025
$1.0M
NIDA NIH HHS K23 DA053989NIDA NIH HHS R01 DA047347NIH HHS K23DA053989NIH HHS R01DA047347
6 · The paper itself

Abstract

backgroundOpioid-involved overdose deaths continue to rise in the US, despite availability of highly effective treatments for opioid use disorder (OUD), in part due to the insufficient number of treatment providers. Barriers include the need for providers to gain expertise and confidence in providing MOUD to their patients who need these treatments. To mitigate this barrier, New Jersey sponsored a buprenorphine training program with financial incentives for participation, which met the then existing requirement for the DATA-2000 waiver. In a 2019 follow-up survey, participants reported on barriers and facilitators to subsequent buprenorphine prescribing.

methodsParticipants in the training program completed a 10-min electronic survey distributed via email. The survey addressed demographics, practice characteristics, current buprenorphine prescribing, and barriers and facilitators to adoption and/or scale up of buprenorphine prescribing.

resultsOf the 440 attendees with a valid email address, 91 individuals completed the survey for a response rate of 20.6%. Of the 91 respondents, 89 were eligible prescribers and included in the final analysis. Respondents were predominantly female (n = 55, 59.6%) and physicians (n = 55, 61.8%); representing a broad range of specialties and practice sites. 65 (73%) of respondents completed the training and DEA-registration, but only 31 (34.8%) were actively prescribing buprenorphine. The most frequently cited barriers to buprenorphine prescribing were lack of access to support services such as specialists in addiction, behavioral health services, and psychiatry. The most frequently reported potential facilitators were integrated systems with direct access to addiction specialists and psychosocial services, easier referral to behavioral health services, more institutional support, and improved guidance on clinical practice standards for OUD treatment.

conclusionMore than half (52.3%) of those who completed incentivized training and DEA registration failed to actively prescribe buprenorphine. Results highlight provider perceptions of inadequate availability of support for the complex needs of patients with OUD and suggest that broader adoption of buprenorphine prescribing will require scaling up support to clinicians, including increased availability of specialized addiction and mental health services.

Indexed as

BuprenorphineOpioid-Related DisordersFemaleHumansMaleNew JerseyOpiate Substitution TreatmentPractice Patterns, Physicians'Surveys and QuestionnairesBuprenorphineBarriersBased addiction treatmentBuprenorphineFacilitatorsOfficeOpioid use disorderPrescribingSurvey

Identifiers

PMID38331802
PMCPMC10851589
OpenAlexW4391651657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.